Relay-Version: version B 2.10 5/3/83; site utzoo.UUCP
Posting-Version: version B 2.10.3 4.3bsd-beta 6/6/85; site ucbvax.BERKELEY.EDU
Path: utzoo!decvax!ittatc!dcdwest!sdcsvax!ucbvax!wharton-10.ARPA!curley
From: curley@wharton-10.ARPA ("ROBERT CURLEY")
Newsgroups: mod.computers.vax
Subject: DECUS Communication
Message-ID: <8607091844.AA03807@ucbvax.Berkeley.EDU>
Date: Mon, 7-Jul-86 21:10:00 EDT
Article-I.D.: ucbvax.8607091844.AA03807
Posted: Mon Jul  7 21:10:00 1986
Date-Received: Thu, 10-Jul-86 20:55:52 EDT
Sender: daemon@ucbvax.BERKELEY.EDU
Reply-To: "ROBERT CURLEY" <curley@wharton-10.ARPA>
Organization: The ARPA Internet
Lines: 27
Approved: info-vax@sri-kl.arpa

I have just become a Director of DECUS.  I was third in a field of five with
three open slots in the election this Spring.  Thank you for the votes.

There has been some comment about the Board being unapproachable and already
knowing what you want.  I would appreciate your comments on the following two 
questions that concern me greatly - or any comments you would share with the
"new guy on the block."

1.  What should be the important points in a DECUS Commercialism Policy?
What should or should not be permitted in the Newsletters, at Symposia or in
the Exhibit Area?  There is a real need, I think, for simple, understandable
rules - before we become a trade arena rather than a technical forum.

2.  Why is Symposia attendance declining?  Or, why are half the attendees
at each Symposium "first timers"?  Why don't you come more often?

Thank you for your time and consideration,

Bob Curley
Department of Radiation Therapy
University of Pennsylvania
Room 410 - 133 South 36th Street
Philadelphia, PA 19104-3246

(voice) 215-662-3083
(ARPA ) CURLEY@WHARTON
------